BRAF and melanoma: WGA also offers the opportunity to uncover previously unknown (perhaps patient-specific) mutations in melanoma genomes and to explore whether particular profiles of mutations or polymorphisms may be predictive of benefit from a particular therapy (i.e., BRAF inhibitors, HD IL-2) [35].